<DOC>
	<DOC>NCT00002171</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count &lt;= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.</brief_summary>
	<brief_title>A Study of Viracept in HIV-Positive Women</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV infection. CD4 T cell count &lt;= 400 cells/mm3. Exclusion Criteria Prior Medication: Excluded: Prior therapy or less than 1 month of therapy with d4T and/or 3TC. Prior protease inhibitor therapy.</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>